Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Physicians are voicing growing frustration with payer policies that delay payments, deny necessary care and add administrative burdens. From preauthorization headaches to reimbursement struggles, nine ...

If you’re considering enrolling in a Medicare Advantage plan (also known as Medicare Part C) in Colorado to meet your various ...

A powerful storm prompted evacuations and flooded burn areas in Pacific Palisades, Altadena and Pasadena while efforts to remove debris and hazardous materials continued Friday. The city of Los ...